BG
RGNX icon

Bellevue Group’s Regenxbio RGNX Stock Holding History

Bellevue Group’s Portfolio RGNX Stock Details RGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-12,000
Closed -$253K – 173
2024
Q1 		$253K Buy
+12,000
New +$214K ﹤0.01% 151
2020
Q3 		– Sell
-41,000
Closed -$1.51M – 221
2020
Q2 		$1.51M Buy
41,000
+4,100
+11% +$153K 0.02% 140
2020
Q1 		$1.2M Buy
36,900
+16,000
+77% +$667K 0.02% 140
2019
Q4 		$856K Sell
20,900
-12,800
-38% -$506K 0.01% 151
2019
Q3 		$1.2M Buy
33,700
+600
+2% +$24.3K 0.02% 138
2019
Q2 		$1.7M Hold
33,100
– – 0.03% 134
2019
Q1 		$1.9M Buy
33,100
+9,800
+42% +$485K 0.1% 111
2018
Q4 		$977K Hold
23,300
– – 0.06% 116
2018
Q3 		$1.76M Sell
23,300
-500
-2% -$36K 0.11% 107
2018
Q2 		$1.71M Buy
+23,800
New +$1.14M 0.15% 94

Other funds holding RGNX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.53B AUM 154.61% 1-Year Est. Return

Bellevue Group's RGNX Position: Q2 2024 in Review

Bellevue Group sold out of Regenxbio (RGNX) in Q2 2024, closing a stake of 12,000 shares — an estimated $253K sold.

Bellevue Group first reported a position in RGNX in Q2 2018 and held it in 10 quarters. The position peaked at $1.9M in Q1 2019. 181 funds tracked by Wall St. Rank hold RGNX as of Q2 2024.

  • Bellevue Group reported no remaining Regenxbio position as of Q2 2024 after selling out during the quarter.
  • Bellevue Group sold 12,000 Regenxbio shares in Q2 2024, an estimated $253K.
  • Bellevue Group first reported a position in Regenxbio in Q2 2018 and held it in 10 quarters.
  • Bellevue Group's Regenxbio position peaked at $1.9M in Q1 2019.
  • 181 funds tracked by Wall St. Rank held Regenxbio as of Q2 2024.

Based on Bellevue Group's 13F filing for Q2 2024, filed 14 Aug 2024.